10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2018 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 22, 2019) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Net Sales | $ 30,578 | 27,390 | 20,853 |
| Cost of products sold, excluding amortization of intangible assets | 12,706 | 12,409 | 9,094 |
| Amortization of intangible assets | 2,178 | 1,975 | 550 |
| Research and development | 2,300 | 2,260 | 1,447 |
| Selling, general and administrative | 9,744 | 9,182 | 6,736 |
| Total Operating Cost and Expenses | 26,928 | 25,826 | 17,827 |
| Operating Earnings | 3,650 | 1,564 | 3,026 |
| Interest expense | 826 | 904 | 431 |
| Interest income | (105) | (124) | (99) |
| Net foreign exchange (gain) loss | 28 | (34) | 495 |
| Debt extinguishment costs | 167 | ||
| Other (income) expense, net | (139) | (1,413) | 786 |
| Earnings from Continuing Operations Before Taxes | 2,873 | 2,231 | 1,413 |
| Taxes on Earnings from Continuing Operations | 539 | 1,878 | 350 |
| Earnings from Continuing Operations | 2,334 | 353 | 1,063 |
| Earnings from Discontinued Operations, net of taxes | 34 | 124 | 321 |
| Gain on sale of Discontinued Operations, net of taxes | 16 | ||
| Net Earnings from Discontinued Operations, net of taxes | 34 | 124 | 337 |
| Net Earnings | 2,368 | 477 | 1,400 |
| Basic Earnings Per Common Share | |||
| Continuing Operations (in dollars per share) | 1.32 | 0.20 | 0.71 |
| Discontinued Operations (in dollars per share) | 0.02 | 0.07 | 0.23 |
| Net Earnings (in dollars per share) | 1.34 | 0.27 | 0.94 |
| Diluted Earnings Per Common Share | |||
| Continuing Operations (in dollars per share) | 1.31 | 0.20 | 0.71 |
| Discontinued Operations (in dollars per share) | 0.02 | 0.07 | 0.23 |
| Net Earnings (in dollars per share) | 1.33 | 0.27 | 0.94 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,758 | 1,740 | 1,477 |
| Dilutive Common Stock Options (in shares) | 12 | 9 | 6 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,770 | 1,749 | 1,483 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 5 | ||
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2018 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 22, 2019) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Net Earnings | $ 2,368 | 477 | 1,400 |
| Foreign currency translation gain (loss) adjustments | (1,460) | 1,365 | (130) |
| Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $47 in 2018, $(61) in 2017 and $(125) in 2016 | 132 | (243) | (326) |
| Unrealized gains (losses) on marketable equity securities, net of taxes of $(76) in 2017 and $(28) in 2016 | 64 | (134) | |
| Net gains (losses) on derivative instruments designated as cash flow hedges, net of taxes of $50 in 2018, $(43) in 2017 and $(4) in 2016 | 136 | (134) | (15) |
| Other Comprehensive Income (Loss) | (1,192) | 1,052 | (605) |
| Comprehensive Income | 1,176 | 1,529 | 795 |
| Supplemental Accumulated Other Comprehensive Income (Loss) Information as of December 31: | |||
| Cumulative foreign currency translation (loss) adjustments | (4,912) | (3,452) | (4,959) |
| Net actuarial (losses) and prior service (costs) and credits | (2,726) | (2,521) | (2,284) |
| Cumulative unrealized gains (losses) on marketable equity securities | (5) | (69) | |
| Cumulative gains (losses) on derivative instruments designated as cash flow hedges | 52 | (84) | 49 |
| Accumulated other comprehensive income (loss) | (7,586) | (6,062) | (7,263) |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2018 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 22, 2019) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 2,368 | 477 | 1,400 |
| Adjustments to reconcile net earnings to net cash from operating activities - | |||
| Depreciation | 1,100 | 1,046 | 803 |
| Amortization of intangible assets | 2,178 | 1,975 | 550 |
| Share-based compensation | 477 | 406 | 310 |
| Impact of currency devaluation | 480 | ||
| Amortization of inventory step-up | 32 | 907 | |
| Investing and financing losses, net | 126 | 47 | 86 |
| Loss on extinguishment of debt | 167 | ||
| Amortization of bridge financing fees | 5 | 165 | |
| Gains on sale of businesses | (1,163) | (25) | |
| Mylan N.V. equity investment adjustment | 947 | ||
| Gain on sale of Mylan N.V. shares | (45) | ||
| Trade receivables | (190) | (207) | (177) |
| Inventories | (514) | 249 | (98) |
| Prepaid expenses and other assets | 23 | 109 | 113 |
| Trade accounts payable and other liabilities | 747 | 615 | (652) |
| Income taxes | (214) | 1,149 | (699) |
| Net Cash From Operating Activities | 6,300 | 5,570 | 3,203 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (1,394) | (1,135) | (1,121) |
| Acquisitions of businesses and technologies, net of cash acquired | (17,183) | (80) | |
| Proceeds from business dispositions | 48 | 6,042 | 25 |
| Proceeds from the sale of Mylan N.V. shares | 2,704 | ||
| Purchases of investment securities | (131) | (210) | (2,823) |
| Proceeds from sales of investment securities | 73 | 129 | 3,709 |
| Other | 48 | 35 | 42 |
| Net Cash From (Used in) Investing Activities | (1,356) | (9,618) | (248) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | (26) | (1,034) | (1,767) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 4,009 | 6,742 | 14,934 |
| Repayments of long-term debt and debt with maturities over 3 months | (12,433) | (8,650) | (12) |
| Payment of bridge financing fees | (170) | ||
| Purchase of Alere preferred stock | (710) | ||
| Acquisition and contingent consideration payments related to business acquisitions | (13) | (25) | |
| Purchases of common shares | (238) | (117) | (522) |
| Proceeds from stock options exercised | 271 | 350 | 248 |
| Dividends paid | (1,974) | (1,849) | (1,539) |
| Net Cash From (Used in) Financing Activities | (10,391) | (5,281) | 11,147 |
| Effect of exchange rate changes on cash and cash equivalents | (116) | 116 | (483) |
| Net Increase (Decrease) in Cash and Cash Equivalents | (5,563) | (9,213) | 13,619 |
| Cash and Cash Equivalents, Beginning of Year | 9,407 | 18,620 | 5,001 |
| Cash and Cash Equivalents, End of Period | 3,844 | 9,407 | 18,620 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 740 | 570 | 620 |
| Interest paid | 845 | 917 | 181 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2018 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2018 10-K (Filed: Feb 22, 2019) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2018 | Dec 31, 2017 | |
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 3,844 | 9,407 |
| Investments, primarily bank time deposits and U.S. treasury bills | 242 | 203 |
| Trade receivables, less allowances of - 2018: $314; 2017: $294 | 5,182 | 5,249 |
| Inventories: | ||
| Finished products | 2,407 | 2,339 |
| Work in process | 499 | 472 |
| Materials | 890 | 790 |
| Total inventories | 3,796 | 3,601 |
| Prepaid expenses and other receivables | 1,559 | 1,667 |
| Current assets held for disposition | 9 | 20 |
| Total Current Assets | 14,632 | 20,147 |
| Investments | 897 | 883 |
| Property and Equipment, at Cost: | ||
| Land | 501 | 526 |
| Buildings | 3,555 | 3,613 |
| Equipment | 10,756 | 10,394 |
| Construction in progress | 894 | 732 |
| Property and equipment, at cost | 15,706 | 15,265 |
| Less: accumulated depreciation and amortization | 8,143 | 7,658 |
| Net Property and Equipment | 7,563 | 7,607 |
| Intangible Assets, net of amortization | 18,942 | 21,473 |
| Goodwill | 23,254 | 24,020 |
| Deferred Income Taxes and Other Assets | 1,868 | 1,944 |
| Non-current Assets Held for Disposition | 17 | 176 |
| Total Assets | 67,173 | 76,250 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 200 | 206 |
| Trade accounts payable | 2,975 | 2,402 |
| Salaries, wages and commissions | 1,182 | 1,187 |
| Other accrued liabilities | 3,780 | 3,811 |
| Dividends payable | 563 | 489 |
| Income taxes payable | 305 | 309 |
| Current portion of long-term debt | 7 | 508 |
| Total Current Liabilities | 9,012 | 8,912 |
| Long-term Debt | 19,359 | 27,210 |
| Post-employment obligations, deferred income taxes and other long-term liabilities | 8,080 | 9,030 |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2018: 1,971,189,465; 2017: 1,965,908,188 | 23,512 | 23,206 |
| Common shares held in treasury, at cost - Shares: 2018: 215,570,043; 2017: 222,305,719 | (9,962) | (10,225) |
| Earnings employed in the business | 24,560 | 23,978 |
| Accumulated other comprehensive income (loss) | (7,586) | (6,062) |
| Total Abbott Shareholders' Investment | 30,524 | 30,897 |
| Noncontrolling Interests in Subsidiaries | 198 | 201 |
| Total Shareholders' Investment | 30,722 | 31,098 |
| Total Liabilities and Shareholders' Investment | 67,173 | 76,250 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2018 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |